The Fontan Dapagliflozin Pilot Study (FonDap)

Background: Patients with Fontan are prone to sequelae related to chronic elevations in central venous pressures. Interventions that improve venous pressures without compromising ventricular filling may therefore be of benefit. Methods We conducted a multi-center, open label, single arm pilot study of 4 weeks of dapagliflozin 10mg in adult patients with Fontan. The primary outcome was change in resting peripheral venous pressure (PVP). Secondary outcomes included changes in post-exercise PVP, peak VO2, Ve/VCO2, oxygen pulse, oxygen uptake efficiency slope (OUES), total body water, and patient reported health status according to the ACHD PRO. Results The total of 29 patients were enrolled bet